Kenneth L. Waggoner - Aug 10, 2021 Form 3 Insider Report for PharmaCyte Biotech, Inc. (PMCB)

Role
Chairman, CEO, Pres and GC, Director
Signature
/s/ Kenneth L. Waggoner
Stock symbol
PMCB
Transactions as of
Aug 10, 2021
Transactions value $
$0
Form type
3
Date filed
8/31/2021, 06:25 PM
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding PMCB Common Stock 20.6K Aug 10, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding PMCB Stock Option (right to buy) Aug 10, 2021 Common Stock 3K $156.00 Direct F1, F2
holding PMCB Stock Option (right to buy) Aug 10, 2021 Common Stock 3K $83.70 Direct F1, F2
holding PMCB Stock Option (right to buy) Aug 10, 2021 Common Stock 3K $74.25 Direct F1, F2
holding PMCB Stock Option (right to buy) Aug 10, 2021 Common Stock 3K $61.20 Direct F1, F2
holding PMCB Stock Option (right to buy) Aug 10, 2021 Common Stock 3K $10.05 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The number of shares has been adjusted to reflect a one-for-1,500 reverse stock split of the Issuer's common stock effected on July 12, 2021 (the "Reverse Split").
F2 The exercise price has been adjusted to reflect the Reverse Split.
F3 The option vested in twelve equal monthly installments beginning on January 1, 2021.